Patient Perception Survey Shows Lack of Education, Assessment of Cancer-Related Fatigue
Results of a perception survey revealed major deficits in education, screening, and treatment among patients with cancer.
Side-Effect Management
Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
[Cancer Management and Research] Researchers present a simple classification method for assessing fatigue, which is proven to be a prognostic marker of TTP and OS in patients with HCC.
Can Weighted Blankets Reduce Patient Anxiety During Outpatient Chemotherapy Infusions?
This crossover study evaluated the effects of using standard-weight weighted blankets as a source of increased deep touch pressure.
Persistent Radiation-Induced Alopecia: Dose Dependence and Treatment
This retrospective cohort analysis sought to determine the association between pRIA and radiation dose and response to treatment.
Strategies for Managing AEs, Patient Adherence in Acalabrutinib for Mantle Cell Lymphoma
Researchers at UT MD Anderson Cancer Center in Houston present tools that support patient adherence to acalabrutinb in the setting of MCL.
MASCC/ISOO Updates Its Guidelines on Preventing, Treating Mucositis Associated With Cancer Therapy
MASCC/ISOO Mucositis Guidelines Leadership Group released updated recommendations and suggestions for preventing and treating oral mucositis in patients undergoing cancer treatment.
Cancer Risk in Individuals With a Chronic Disability
In a recent analysis, the prevalence and age at diagnosis of 4 common cancers was compared in individuals with and without specific types of pre-existing disabilities.
Management of Imatinib-Associated Severe Skin Rash That Avoids Dose Reduction or Treatment Interruption
A small study sought to determine if severe treatment-related skin rash could be treated without dose reduction or interruption in patients receiving imatinib for GIST.
New Evidence Supports Update of ASCO Guidelines on Prevention, Treatment of CIPN
A literature search of new studies clarifies, refutes, and expands on previous recommendations for managing new and established CIPN in patients treated with cytotoxic agents.
Identifying Risk Factors for Invasive Fungal Infection in Ibrutinib-Treated CLL Patients
Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.
-
Loading...
-
Loading...
Next post in Leukemia
